These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16079891)

  • 21. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.
    Roboz GJ; Knovich MA; Bayer RL; Schuster MW; Seiter K; Powell BL; Woodruff RD; Silver RT; Frankel AE; Feldman EJ
    Leuk Lymphoma; 2002 Oct; 43(10):1951-5. PubMed ID: 12481890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    van der Heiden PL; Jedema I; Willemze R; Barge RM
    Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
    Estey EH; Thall PF; Giles FJ; Wang XM; Cortes JE; Beran M; Pierce SA; Thomas DA; Kantarjian HM
    Blood; 2002 Jun; 99(12):4343-9. PubMed ID: 12036860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
    Radsak MP; Salih HR; Sökler M; Kanz L; Denzlinger C
    Leukemia; 2002 Sep; 16(9):1870-1. PubMed ID: 12200709
    [No Abstract]   [Full Text] [Related]  

  • 25. Current use and future development of gemtuzumab ozogamicin.
    Larson RA
    Semin Hematol; 2001 Jul; 38(3 Suppl 6):24-31. PubMed ID: 11474494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stadtmauer EA
    Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
    Ferrara F; Fazi P; Venditti A; Pagano L; Amadori S; Mandelli F
    Hematol Oncol; 2008 Jun; 26(2):104-7. PubMed ID: 18271064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.
    Nabhan C; Rundhaugen LM; Riley MB; Rademaker A; Boehlke L; Jatoi M; Tallman MS
    Leuk Res; 2005 Jan; 29(1):53-7. PubMed ID: 15541475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
    Buckwalter M; Dowell JA; Korth-Bradley J; Gorovits B; Mayer PR
    J Clin Pharmacol; 2004 Aug; 44(8):873-80. PubMed ID: 15286091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
    Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M
    Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
    Leopold LH; Berger MS; Feingold J
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).
    de Vetten MP; Jansen JH; van der Reijden BA; Berger MS; Zijlmans JM; Löwenberg B
    Br J Haematol; 2000 Oct; 111(1):277-9. PubMed ID: 11091212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia.
    McHayleh W; Foon K; Redner R; Sehgal R; Raptis A; Agha M; Luong TM; Schlesselman JJ; Boyiadzis M
    Cancer; 2010 Jun; 116(12):3001-5. PubMed ID: 20564405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
    Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
    Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stasi R; Evangelista ML; Buccisano F; Venditti A; Amadori S
    Cancer Treat Rev; 2008 Feb; 34(1):49-60. PubMed ID: 17942233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
    Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
    Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
    Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Gaitani S; Visani G; Baccarani M
    Leuk Res; 2004 Sep; 28(9):987-90. PubMed ID: 15234577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
    Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
    Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
    Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
    Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.